Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice (Q36904857)

17 August 2017

1 reference

title

Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice (English)

1 reference

17 August 2017

Cristina Hernández

1

1 reference

PubMed ID

17685870

17 August 2017

Rafael Simó

series ordinal

2

1 reference

PubMed ID

17685870

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

1 reference

17 August 2017

16

1 reference

17 August 2017

8

1 reference

17 August 2017

1209-1226

1 reference

The 14-year incidence of visual loss in a diabetic population.

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Association of macular involvement with proliferative retinopathy in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Ten years after the Diabetic Retinopathy Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

VEGF localisation in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Novel approaches in the treatment of angiogenic eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Gene therapy for ocular angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Recent developments in ocular gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Gene therapy for ocular neovascularization: a cure in sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Protein kinase C activation and the development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Mitogen-activated protein kinases as glucose transducers for diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Vascular endothelial growth factor expression and secretion by retinal pigment epithelial cells in high glucose and hypoxia is protein kinase C-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Drug delivery systems for vitreoretinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Human retinal molecular weight exclusion limit and estimate of species variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Novel approaches for retinal drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Review: practical issues in intravitreal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Inhibitors of ocular neovascularization: promises and potential problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Diabetic macular edema: classification, medical and laser therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

New and improved glucocorticoid receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Adeno-associated viral vectors for retinal gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pharmacologically regulated gene expression in the retina following transduction with viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Isolation of retinal progenitor cells from post-mortem human tissue and comparison with autologous brain progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Facile isolation and the characterization of human retinal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Neural progenitor cells from postmortem adult human retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Hematopoietic stem cells provide repair functions after laser-induced Bruch's membrane rupture model of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Retinal repair by transplantation of photoreceptor precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

SDF-1 is both necessary and sufficient to promote proliferative retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Topical application of integrin antagonists inhibits proliferative retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

The effect of angiostatin on vascular leakage and VEGF expression in rat retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Adeno-associated virus-mediated expression of vascular endothelial growth factor peptides inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.8.1209

10.1517/13543784.16.8.1209

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17685870